Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

Mycopathologia

Volumn 171, Issue 2, 2011, Pages 111-117

  Sun, Yi ^a   Liu, Wei ^a   Wan, Zhe ^a   Wang, Xiaohong ^a   Li, Ruoyu ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antifungal activity; Drug combinations; Exophiala dermatitidis; Phaeohyphomycosis

Indexed keywords

CHAETOTHYRIALES; EXOPHIALA; EXOPHIALA DERMATITIDIS;

EID: 78651386039     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9358-6     Document Type: Article

References (40)

1. McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 1983; 8: 1-16.
2. Oztas E, Odemis B, Kekilli M, Kurt M, Dinc BM, Parlak E, et al. Systemic phaeohyphomycosis caused by Exophiala Dermatitidis resembling primary sclerosing cholangitis. J Med Microbiol. 2009; 58: 1243-6.
3. Alabaz D, Kibar F, Arikan S, Sancak B, Celik U, Aksaray N, et al. Systemic phaeohyphomycosis due to Exophiala (Wangiella) in an immunocompetent child. Med Mycol. 2009; 31: 1-5.
4. Hiruma M, Kawada A, Ohata H, Ohnishi Y, Takahashi H, Yamazaki M, et al. Systemic phaeohyphomycosis caused by Exophiala dermatitidis. Mycoses. 1993; 36: 1-7.
5. Li DM, de Hoog GS. Cerebral phaeohyphomycosis-a cure at what lengths? Lancet Infect Dis. 2009; 9: 376-83.
6. Chang X, Li R, Yu J, Bao X, Qin J. Phaeohyphomycosis of the central nervous system caused by Exophiala dermatitidis in a 3-year-old immunocompetent host. J Child Neurol. 2009; 24: 342-5.
7. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol. 2002; 40: 3776-81.
8. Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol. 2009; 47: 41-3.
9. Okeke CN, Gugnani HC. In vitro sensitivity of environmental isolates of pathogenic dematiaceous fungi to azole compounds and a phenylpropyl-morpholine derivative. Mycopathologia. 1987; 99: 175-81.
10. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard-M38-A2. CLSI, Wayne, PA, USA, 2008.
11. Denning DW. Echinocandin antifungal drugs. Lancet. 2003; 362: 1142-51.
12. Sudhadham M, de Hoog GS, Menken SB, Gerrits VDEA, Sihanonth P. Rapid screening for genotypes as possible markers of virulence in the neurotropic black yeast Exophiala dermatitidis using PCR-RFLP. J Microbiol Methods. 2010; 80: 138-42.
13. Li DM, Li RY, de Hoog GS, Wang DL. Exophiala asiatica, a new species from patient with phaeohyphomycosis. Med Mycol. 2009; 47: 101-9.
14. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001; 39: 954-8.
15. Odds FC. Synergy, antagonism, what the chequerboard puts between them. J Antimicrob Chemother. 2003; 52: 1.
16. Meletiadis J, Meis J, de Hoog GS, Verweij PE. In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs. Mycoses. 2000; 43: 309-12.
17. Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opin Pharmacother. 2009; 10: 2723-33.
18. Neoh CY, Tan SH, Perera P. Cutaneous phaeohyphomycosis due to Cladophialophora bantiana in an immunocompetent patient. Clin Exp Dermatol. 2007; 32: 539-40.
19. Revankar SG. Therapy of infections caused by dematiaceous fungi. Expert Rev Anti Infect Ther. 2005; 3: 601-12.
20. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 2000; 44: 470-2.
21. Laniado-Laborin R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009; 26: 223-7.
22. Mukaino T, Koga T, Oshita Y, Narita Y, Obata S, Aizawa H. Exophiala dermatitidis infection in non-cystic fibrosis bronchiectasis. Respir Med. 2006; 100: 2069-71.
23. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003; 187: 1834-43.
24. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003; 97: 1025-32.
25. Horre R, Schaal KP, Siekmeier R, Sterzik B, de Hoog GS, Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration. 2004; 71: 360-6.
26. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Dohmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr. 1992; 151: 344-6.
27. Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis. 2001; 33: 777-9.
28. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol. 2008; 25: 101-6.
29. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008; 21: 580-6.
30. St-Germain G, Laverdiere M, Pelletier R, Rene P, Bourgault AM, Lemieux C, et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol. 2008; 19: 55-62.
31. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006; 52: 133-7.
32. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005; 106: 2641-5.
33. Cao C, Liu W, Li R, Wan Z, Qiao J. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei. J Antimicrob Chemother. 2009; 63: 340-2.
34. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006; 58: 1168-76.
35. Kiraz N, Dag I, Yamac M, Demchok JP, Walsh TJ. Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrob Agents Chemother. 2009; 53: 788-90.
36. Colombo AL, Rosas RC. Successful treatment of an Aspergillus brain abscess with caspofungin: case report of a diabetic patient intolerant of amphotericin B. Eur J Clin Microbiol Infect Dis. 2003; 22: 575-6.
37. Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST, et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol. 2004; 42: 5950-3.
38. Gubler C, Wildi SM, Imhof A, Schneemann M, Mullhaupt B. Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole. Infection. 2007; 35: 364-6.
39. Damaj G, Ivanov V, Le BB, D'incan E, Doglio MF, Bilger K, et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann Hematol. 2004; 83: 390-3.
40. Gea-Banacloche JC, Peter J, Bishop M, Kasten-Sportes C, Fowler D, et al. Successful treatment of invasive aspergillosis with the combination of voriconazole and caspofungin: correlation with in vitro interactions. Program and abstracts the 43rd Annual ICAAC; September 14-17, 2003; Chicago, IL. Abstract M-1759.